Portmann L, Fitch F W, Havran W, Hamada N, Franklin W A, DeGroot L J
Department of Medicine, University of Chicago, Illinois 60637.
J Clin Invest. 1988 Apr;81(4):1217-24. doi: 10.1172/JCI113438.
MAb directed to the thyroid microsomal antigen have been developed. All bound to 101- and 107-kD bands in Western blot analysis using thyroid microsomal fraction as antigen. The MAb also bound to microsomal proteins immunoprecipitated by serum from patients having a high titer of anti-microsomal antibody but no antibodies to thyroglobulin or thyrotropin-stimulating hormone receptor. The pattern of binding was related to the amount of reducing agent. The 101- and 107-kD bands were increased by addition of dithiothreitol whereas, in its absence, numerous bands of higher molecular weight were present, suggesting a multimeric protein structure. Despite the inability to immunoprecipitate thyroid peroxidase (TPO) enzymatic activity, the MAb bound intensively in Western blot to denatured purified hog TPO and to denatured immunopurified human TPO. Trypsin digestion of the 101-107-kD antigen produced a doublet of 84-88 kD that was still immunoreactive with MAb. One of five polyclonal sera tested (with a microsomal antibody titer greater than 1/20,480 measured by the tanned red cell hemagglutination technique) also recognized the 84-88 kD trypsin fragments. Addition of V8 protease led to a disappearance of the 107-kD protein, but not the 101-kD protein, proving that this antigen is formed by two different polypeptides. The MAb bound strongly to thyroid epithelium, whereas binding to papillary carcinoma was absent or low and moderate for follicular and Hurthle cell carcinoma. This study indicates that the thyroid microsomal antigen and TPO are identical and are constituted of two different polypeptides. On SDS-PAGE the antigen appears as two contiguous bands which share common epitopes but are not identical, as proven by their size and difference in susceptibility to proteolytic digestion. The immunoreactivity of the molecule is highly dependent on a trypsin-sensitive site, which appears important in the recognition of the antigen by polyclonal sera and may have biological importance. The expression of microsomal antigenicity is variable among various thyroid carcinomas.
已研制出针对甲状腺微粒体抗原的单克隆抗体(MAb)。在以甲状腺微粒体组分作为抗原的蛋白质免疫印迹分析中,所有这些单克隆抗体均与101-kD和107-kD条带结合。这些单克隆抗体还与由抗微粒体抗体滴度高但无抗甲状腺球蛋白或促甲状腺激素受体抗体的患者血清免疫沉淀的微粒体蛋白结合。结合模式与还原剂的量有关。加入二硫苏糖醇后,101-kD和107-kD条带增加,而在没有二硫苏糖醇的情况下,存在许多更高分子量的条带,提示为多聚体蛋白结构。尽管无法免疫沉淀甲状腺过氧化物酶(TPO)的酶活性,但这些单克隆抗体在蛋白质免疫印迹中与变性的纯化猪TPO以及变性的免疫纯化人TPO强烈结合。对101 - 107-kD抗原进行胰蛋白酶消化产生了84 - 88 kD的双峰,其仍与单克隆抗体发生免疫反应。所检测的五份多克隆血清之一(通过鞣酸红细胞血凝技术测得微粒体抗体滴度大于1/20,480)也识别84 - 88 kD的胰蛋白酶片段。加入V8蛋白酶导致107-kD蛋白消失,但101-kD蛋白未消失,证明该抗原由两种不同的多肽组成。这些单克隆抗体与甲状腺上皮细胞强烈结合,而与乳头状癌无结合或结合较弱,与滤泡状癌和许特莱细胞癌的结合为中度。本研究表明,甲状腺微粒体抗原与TPO相同,且由两种不同的多肽组成。在十二烷基硫酸钠 - 聚丙烯酰胺凝胶电泳(SDS-PAGE)上,该抗原表现为两条相邻的条带,它们具有共同的表位,但并不相同,这已通过其大小和对蛋白水解消化敏感性的差异得到证实。该分子的免疫反应性高度依赖于一个对胰蛋白酶敏感的位点,该位点在多克隆血清识别抗原中似乎很重要,并且可能具有生物学意义。微粒体抗原性的表达在各种甲状腺癌中存在差异。